JPRN-jRCTs041200108招募中未知
The effects of dapagliflozin on anemia of chronic kidney disease (Study B)
Hamano Takayuki0 个研究点目标入组 96 人开始时间: 2021年3月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Those with CKD stage 3-4 (eGFR 15-59 mL/min/1.73m2) and diabetes mellitus or heart failure with reduced ejection fraction, those with CKD (eGFR 15-59 mL/min/1.73m2) without diabetes mellitus or heart failure with reduced ejection fraction
- •(2) Those with anemia by WHO diagnostic criteria (Hb <13 g/dL for men or Hb < 12g/dL for women) with normal or low serum erythropoietin levels and not on erythropoiesis stimulating agents (ESA) or hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors
- •(3) Those without iron deficiency (transferrin saturation >= 20% or ferritin >= 50 ng/mL)
- •(4) Those who are not on SGLT2 inhibitors
- •(5) Those who gave informed consent
- •(6) Age >= 20 years old at the time of consent (both men and women, and inpatients and outpatients)
- •(7) For those with heart failure with reduced ejection fraction, they should be on standard therapy for heart failure (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, or beta blockers)
排除标准
- •(1) Those with history of allergy to dapagliflozin
- •(2) Those with severe ketoacidosis, hyperosmolar coma or precoma, or type 1 diabetes
- •(3) Those with hospitalization due to infection, surgery under general anesthesia, trauma requiring surgical intervention, gastrointestinal bleeding, transfusion, active malignancy within 3 months, or those expecting surgery within 3 months
- •(4) Those with non-adherence
- •(5) Pregnant or potentially pregnant women
- •(6) Those whom treating physicians judge inappropriate candidates for participating in the study
研究者
相似试验
招募中
不适用
The effects of dapagliflozin on anemia of chronic kidney disease (Study A)Chronic kidney disease stage 3-4 and anemia of chronic kidney diseaseDapagliflozin, diabetes mellitus, chronic kidney disease Anemia of chronic kidney disease, heart failure with reduced ejection fractionJPRN-jRCTs041200107Hamano Takayuki96
进行中（未招募）
1 期
Dapagliflozin effect on generation of red blood cells and physical fitness in patients with type 2 diabetes - a randomized, double-blind, controlled, parallel group, exploratory studyPatients with T2DM and hypertension aged 40 to 70 years (including)EUCTR2017-004889-10-DEniversity Hospital Tuebingen75
招募中
3 期
Effect of Dapagliflozin in The Prevention of Iodinated Contrast Media Induced Acute Kidney InjuryAcute kidney injury caused by iodinated contrast agents.Acute kidney failureIRCT20170609034406N11Tabriz University of Medical Sciences80
尚未招募
4 期
Evaluating the effect of Dapagliflozin on Alanine Transaminase Levels in Type 2 Diabetic Patients with Non Alcoholic Fatty Liver Diseaseon Alcoholic SteatohepatitisNon Alcoholic SteatohepatitisMetabolic and Endocrine - DiabetesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonType 2 Diabetes MellitusACTRN12624000039583MTI Lady Reading Hospital192
已完成
不适用
The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trialAutosomal dominant polycystic kidney disease (ADPKD)JPRN-UMIN000046275Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine30